These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 37298120)

  • 1. Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis.
    Zhu Y; Tan JK; Wong SK; Goon JA
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating miRNAs associated with nonalcoholic fatty liver disease.
    Atic AI; Thiele M; Munk A; Dalgaard LT
    Am J Physiol Cell Physiol; 2023 Feb; 324(2):C588-C602. PubMed ID: 36645666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
    Hochreuter MY; Dall M; Treebak JT; Barrès R
    Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Liu CH; Ampuero J; Gil-Gómez A; Montero-Vallejo R; Rojas Á; Muñoz-Hernández R; Gallego-Durán R; Romero-Gómez M
    J Hepatol; 2018 Dec; 69(6):1335-1348. PubMed ID: 30142428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis.
    Xin S; Zhan Q; Chen X; Xu J; Yu Y
    BMC Gastroenterol; 2020 Jun; 20(1):186. PubMed ID: 32532204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis.
    Su Q; Kumar V; Sud N; Mahato RI
    Adv Drug Deliv Rev; 2018 Apr; 129():54-63. PubMed ID: 29391222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Dai W; Xu B; Li P; Weng J
    Am J Ther; 2023 Jan-Feb 01; 30(1):e17-e25. PubMed ID: 36608070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
    Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
    World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
    Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
    J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.